KIR3DL1 and neuroblastoma: In our analyses of associations of KIR/KIR-ligand genotypic influence on clinical response in the neuroblastoma study (ANBL0032), we reported on differences in clinical outcome for those KIR3DL1+/Bw4+ (immunotherapy n = 58; isotretinoin n = 61) and those not KIR3DL1+/Bw4+ (immunotherapy n = 30; isotretinoin n = 25), and differences in response were observed dependent upon treatment type (20, 21).